These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
236 related articles for article (PubMed ID: 23343178)
1. Determination of arsenic metabolites in patients with newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide. Zhang Z; Chen Y; Meng H; Sui M; Zhou Q; Shi C; Han L; Wang H; Zhou J Leuk Lymphoma; 2013 Sep; 54(9):2041-6. PubMed ID: 23343178 [TBL] [Abstract][Full Text] [Related]
2. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Yoshino Y; Yuan B; Miyashita SI; Iriyama N; Horikoshi A; Shikino O; Toyoda H; Kaise T Anal Bioanal Chem; 2009 Jan; 393(2):689-97. PubMed ID: 19009285 [TBL] [Abstract][Full Text] [Related]
3. Speciation of arsenic trioxide metabolites in peripheral blood and bone marrow from an acute promyelocytic leukemia patient. Iriyama N; Yoshino Y; Yuan B; Horikoshi A; Hirabayashi Y; Hatta Y; Toyoda H; Takeuchi J J Hematol Oncol; 2012 Jan; 5():1. PubMed ID: 22272800 [TBL] [Abstract][Full Text] [Related]
4. Clinical pharmacokinetic study of arsenic trioxide in an acute promyelocytic leukemia (APL) patient: speciation of arsenic metabolites in serum and urine. Fukai Y; Hirata M; Ueno M; Ichikawa N; Kobayashi H; Saitoh H; Sakurai T; Kinoshita K; Kaise T; Ohta S Biol Pharm Bull; 2006 May; 29(5):1022-7. PubMed ID: 16651738 [TBL] [Abstract][Full Text] [Related]
5. Time course of arsenic species in red blood cells of acute promyelocytic leukemia (APL) patients treated with single agent arsenic trioxide. Guo M; Wang B; Liu S; Wang W; Gao C; Hu S; Fan S; Hai X; Zhou J Expert Rev Clin Pharmacol; 2019 Apr; 12(4):371-378. PubMed ID: 30795697 [TBL] [Abstract][Full Text] [Related]
6. Arsenic speciation in urine from acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Wang Z; Zhou J; Lu X; Gong Z; Le XC Chem Res Toxicol; 2004 Jan; 17(1):95-103. PubMed ID: 14727923 [TBL] [Abstract][Full Text] [Related]
7. Acute promyelocytic leukemia: recent advances in therapy and molecular basis of response to arsenic therapies. Chou WC; Dang CV Curr Opin Hematol; 2005 Jan; 12(1):1-6. PubMed ID: 15604884 [TBL] [Abstract][Full Text] [Related]
8. Arsenic speciation in saliva of acute promyelocytic leukemia patients undergoing arsenic trioxide treatment. Chen B; Cao F; Yuan C; Lu X; Shen S; Zhou J; Le XC Anal Bioanal Chem; 2013 Feb; 405(6):1903-11. PubMed ID: 23318765 [TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide at conventional dosage does not aggravate hemorrhage in the first-line treatment of adult acute promyelocytic leukemia. Cui W; Wang J; Nie RM; Zhao LL; Gao MQ; Zhu HM; Chen L; Hu J; Li JM; Shen ZX; Wang ZY; Chen SJ; Chen Z; Wang KK; Xi XD; Mi JQ Eur J Haematol; 2018 Apr; 100(4):344-350. PubMed ID: 29266395 [TBL] [Abstract][Full Text] [Related]
10. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement. Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415 [TBL] [Abstract][Full Text] [Related]
11. Arsenic trioxide and acute promyelocytic leukemia: clinical and biological. Chen Z; Zhao WL; Shen ZX; Li JM; Chen SJ; Zhu J; Lallemand-Breittenbach V; Zhou J; Guillemin MC; Vitoux D; de Thé H Curr Top Microbiol Immunol; 2007; 313():129-44. PubMed ID: 17217042 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of arsenic species in Japanese patients with relapsed or refractory acute promyelocytic leukemia treated with arsenic trioxide. Fujisawa S; Ohno R; Shigeno K; Sahara N; Nakamura S; Naito K; Kobayashi M; Shinjo K; Takeshita A; Suzuki Y; Hashimoto H; Kinoshita K; Shimoya M; Kaise T; Ohnishi K Cancer Chemother Pharmacol; 2007 Mar; 59(4):485-93. PubMed ID: 16937107 [TBL] [Abstract][Full Text] [Related]
13. Speciation of arsenic trioxide penetrates into cerebrospinal fluid in patients with acute promyelocytic leukemia. Kiguchi T; Yoshino Y; Yuan B; Yoshizawa S; Kitahara T; Akahane D; Gotoh M; Kaise T; Toyoda H; Ohyashiki K Leuk Res; 2010 Mar; 34(3):403-5. PubMed ID: 19733394 [TBL] [Abstract][Full Text] [Related]
14. Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma. Fox E; Razzouk BI; Widemann BC; Xiao S; O'Brien M; Goodspeed W; Reaman GH; Blaney SM; Murgo AJ; Balis FM; Adamson PC Blood; 2008 Jan; 111(2):566-73. PubMed ID: 17959855 [TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia. Leu L; Mohassel L Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784 [TBL] [Abstract][Full Text] [Related]
16. Swallowing a bitter pill-oral arsenic trioxide for acute promyelocytic leukemia. Torka P; Al Ustwani O; Wetzler M; Wang ES; Griffiths EA Blood Rev; 2016 May; 30(3):201-11. PubMed ID: 26709030 [TBL] [Abstract][Full Text] [Related]
17. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Zhou J; Zhang Y; Li J; Li X; Hou J; Zhao Y; Liu X; Han X; Hu L; Wang S; Zhao Y; Zhang Y; Fan S; Lv C; Li L; Zhu L Blood; 2010 Mar; 115(9):1697-702. PubMed ID: 20029047 [TBL] [Abstract][Full Text] [Related]
18. Monomethylated arsenic was the Major methylated arsenic in Red blood cells of acute promyelocytic leukemia patients treated with arsenic trioxide. Guo S; Wang X; Gao C; Wu Z; Chen H; Lin L; Guo M; Gao Y; Hai X Toxicol Lett; 2021 Sep; 347():78-85. PubMed ID: 33865921 [TBL] [Abstract][Full Text] [Related]
19. Successful treatment of a case of relapsed acute promyelocytic leukemia with arsenic trioxide. Hirayama Y; Koyama R; Nagai T; Ohta H; Kondo A; Ishikawa K; Ishitani K; Matsunaga T; Sakamaki S; Niitsu Y Intern Med; 2001 Nov; 40(11):1136-9. PubMed ID: 11757771 [TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide for the treatment of acute promyelocytic leukemia. Lam MS; Ignoffo RJ Cancer Pract; 2001; 9(3):155-7. PubMed ID: 11879303 [No Abstract] [Full Text] [Related] [Next] [New Search]